Treatment with teriflunomide may prove effective in people with radiologically isolated syndrome, the presymptomatic phase of multiple sclerosis.
Among people whose magnetic resonance imaging (MRI) scans reveal signs of multiple sclerosis (MS), the immunomodulatory drug teriflunomide was found to delay first MS symptoms, revealed// study to be presented at the American Academy of Neurology’s 75th Annual Meeting, being held in person in Boston and live online from April 22-27, 2023.
What is Multiple Sclerosis
MS is a disease in which the body’s immune system attacks myelin, the fatty white substance that insulates and protects the nerves. Symptoms of MS may include fatigue, numbness, tingling or difficulty walking. “With more and more people having brain scans for various reasons, such as headache or head trauma, more of these cases are being discovered, and many of these people go on to develop MS,” said study author Christine Lebrun Frenay, MD, of the University Hospital of Nice in France and a Fellow of the American Academy of Neurology. “The sooner a person can be treated for MS, the greater the chances of delaying damage to the myelin, which decreases the risk of permanent neurologic impairment and debilitating symptoms.”A New Hope for Multiple Sclerosis: New Treatment
The study involved 89 people with radiologically isolated syndrome. Half of the people were given 14 milligrams (mg) of teriflunomide daily and the other half were given a placebo. They were followed for up to two years.‘Radiologically isolated syndrome is a condition diagnosed in individuals without multiple sclerosis symptoms but who display irregularities in the brain or spinal cord called lesions. ’
During the study, eight people who took the drug developed MS symptoms, compared to 20 who took the placebo. After adjusting for other factors that could affect the risk of developing symptoms, researchers found that people taking teriflunomide had a 72% lower risk of experiencing first symptoms than those taking the placebo.
“However, more research is needed in larger groups of people to confirm our findings. Additionally, it is important that medical professionals are cautious when using MRI expertise to diagnose this condition, selecting only patients at risk of developing MS and not increasing MRI misdiagnoses,” Lebrun Frenay said.
The study was supported by Sanofi, the company that makes teriflunomide.
Source-Eurekalert